Understanding the immune response in Thrombotic Thrombocytopenic Purpura
Official title: Immunological Aspects of Thrombotic Thrombocytopenic Purpura (TTP): Characterisation of B and T Lymphocytes Specific for the ADAMTS13 Autoantigen and Therapeutic Implications
Run by University Hospital, Rouen · NCT06945861 · Data updated 2026-11-12
This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Drugs / interventions | rituximab, caplacizumab |
| Locations | 1 site (Rouen) |
| Status | Recruiting |
| Started | May 11, 2023 |
| Main results expected | May 10, 2027 |
| Study ends | May 11, 2028 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT06945861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old diagnosed with TTP at any stage, whether in acute phase, remission, or relapse.
✕Probably not a fit
Patients who are under guardianship or have been deprived of liberty may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to characterize specific immune cells involved in Thrombotic Thrombocytopenic Purpura (TTP) during both the acute phase and after treatment. It focuses on identifying memory B lymphocytes and autoreactive T lymphocytes, particularly follicular helper T lymphocytes, to understand their role in the disease's progression and treatment response. The study seeks to find early indicators that could predict relapses, which would help in personalizing treatment strategies to maintain remission in patients. By analyzing these immune responses, the research hopes to improve outcomes for patients suffering from TTP.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies that improve remission rates and reduce relapses in TTP patients.
How similar studies have gone: While the specific approach of characterizing immune responses in TTP is novel, similar studies in other autoimmune conditions have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 18 * patients with TTP at any stage of diagnosis (acute phase, lasting remission or not, relapse) * patients undergoing internal medicine at Rouen University Hospital * people who have read and understood the information letter * membership of a social security scheme Exclusion Criteria: \- a person deprived of liberty by an administrative or judicial decision or a person placed under court protection/guardianship or guardianship
Where it's running
-
University Rouen Hospital,
Rouen, France Recruiting
Study contacts
- Study coordinator: David DM MALLET, Director
- Email: david.mallet@chu-rouen.fr
- Phone: 02 32 88 82 65
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
cTTP patients treated with recombinant ADAMTS13: what happened after the early access program
This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.
-
Adzynma in people with congenital TTP: a look at safety and antibody risk
This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.
-
Long-term outcomes for people with immune TTP in the French national TMA cohort
This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).
-
Survey of a treatment for congenital thrombotic thrombocytopenic purpura
This study is testing a new treatment called recombinant ADAMTS13 to see if it helps people with congenital thrombotic thrombocytopenic purpura feel better and stay healthy over 18 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.